NCT03973827View on ClinicalTrials.gov

Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 17, 2019

Primary Completion Date

December 10, 2020

Study Completion Date

November 20, 2024

Conditions
Type1diabetes
Interventions
DRUG

ProTrans

Single infusion of 25, 100 or 200 million cells per patient.

OTHER

Control

No intervention. Control subjects.

Trial Locations (1)

Unknown

Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Huddinge

Sponsors

Lead Sponsor

NextCell Pharma Ab
All Listed Sponsors
lead

NextCell Pharma Ab

INDUSTRY

NCT03973827 - Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes | Biotech Hunter | Biotech Hunter